|BioMed Updates: ELTP.OB, SOMX, STEM, GERN, ASTM, VRTX, CYTR, IMUC.OB, JAV|
|Wednesday, 02 December 2009 18:55|
Below is a summary of BioMed updates from 2-Dec, summarized in 140 characters or less each.
$ELTP.OB / Elite Pharma soars 40% on FDA generic approval opiate pain drug methadone along with ThePharmaNetwork
$JAV / Javelin Pharma files NDA for FDA approval of Dyloject (diclofenac injection) (already approved in Europe)
$SOMX / Somaxon Pharma Awaits FDA Decision (expected 4-Dec) for insomnia drug Silenor (doxepin)
$STEM $GERN $ASTM / HavRx Global Stem Cell Index Up on New Tax-Paid Cell Lines / http://bit.ly/4J83Wi
$VRTX / Vertex Pharma Announces Proposed Public Offering AH, Down 2.5% / 10M shares stock / 1.5M options
New Report on Protox by Dundee Securites Ahead of Key Results (TSX: PRX.TO) (OTC: PTXRF.PK) / http://hub.tm/?kGFaK
$CYTR / CytRx / FDA Lifts Clinical Hold / Will resume clinial trial for arimoclomol in ALS patients
$IMUC.OB / ImmunoCellular Notches Deal with MD Anderson for New Cancer Stem Cell Vaccine Target / http://hub.tm/QOmte
Click here to follow me on twitter / mikehavrilla and check out the BioMedReports.com FDA Calendar service, which includes a database with over 400 entries of (1) pending new drug, biological agent, or medical device new product decisions at the FDA (e.g. NDA, BLA, 510k, PMA, sNDA, and sBLA filings); (2) pending new submissions to the FDA; (3) pending complete response letter resubmissions to the FDA; and (4) pending clinical trial results.
Disclosure: Long IMUC.OB, PTXRF.PK